Bladder Cancer Cells Apoptosis And Bladder Tumour Growth Inhibition Induced By Paclitaxel

IntroductionSeventy percent of newly diagnosed cases of bladder cancer will present with superficial disease. Management of superficial bladder cancer usually consists of transurethral tumor resection of visible tumors and margins followed by adjuvant intravesical chemotherapy to reduce recurrence and/or progression. In-travesical chemotherapy presents a targeting advantage by selectively delivering the drug in high concentration to the tumor - bearing bladder tissue while minimizing systemic exposure. Paclitaxel is one of the most important anticancer a-gents developed in the last two decades, and has shown significant activity a-gainst multiple types of human solid tumors. In patient bladder tumors, paclitaxel inhibits tumor cell proliferation and induces apoptosis, with a greater apoptot-ic effect in the more rapidly proliferating tumors. These results indicate that paclitaxel is a viable candidate for intravesical therapy of bladder cancer, especially for the rapidly proliferating tumors which are relatively insensitive to the currently used drugs such as mitomycin C and doxorubicin. In this study, we evaluated whether or not paclitaxel can induce the inhibition and apoptosis of bladder canner EJ cell line and the period, dosage and effect of paclitaxel on bladder canner EJ cells line are to be observed. Effects and mechanism of intravesical instillation of paclitaxel are to be investigated in orthotopic bladder tumor of rats.MethodsBladder Cancer EJ cells line cultured in vitro were treated by paclitaxel of...